Valuation: Medtide Inc.

Market Cap 251.59Cr 294.94Cr 38Cr 34Cr 31Cr 28Cr 54Cr 3.59TCr 54Cr 376.92Cr 147.55Cr 1.85TCr 141.18Cr 138.05Cr 5.97TCr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 193.7Cr 227.07Cr 29Cr 26Cr 24Cr 22Cr 41Cr 2.77TCr 42Cr 290.19Cr 113.6Cr 1.43TCr 108.69Cr 106.29Cr 4.59TCr EV / Sales 2026 *
3.24x
EV / Sales 2027 * 2.52x
Free-Float
19.48%
Yield 2026 *
-
Yield 2027 * -
1 day-0.48%
1 week+0.49%
Current month-3.81%
1 month+9.76%
3 months-13.75%
6 months-5.91%
Current year-32.09%
1 week 20.28
Extreme 20.28
21.4
1 month 17.64
Extreme 17.64
23.8
Current year 17.64
Extreme 17.64
30.46
1 year 17.64
Extreme 17.64
31.98
3 years 17.64
Extreme 17.64
41.72
5 years 17.64
Extreme 17.64
41.72
10 years 17.64
Extreme 17.64
41.72
Manager TitleAgeSince
Chief Executive Officer 58 11/06/2020
Director of Finance/CFO 50 31/07/2026
Director of Finance/CFO 53 01/10/2020
Director TitleAgeSince
Chairman 58 11/06/2020
Director/Board Member 51 27/01/2022
Director/Board Member 63 27/01/2022
Date Insider Type Main position Quantity % Market Cap. Importance
09/03/26 Other

Chief Executive Officer

6,82,01,112 48.0967%
09/03/26 Other

Director

6,82,01,112 48.0967%
09/03/26 Other

Chief Executive Officer

6,82,01,112 48.0967%
Change 5-day change 1-year change 3-year change Capi.($)
-0.48%+0.49% - - 38Cr
Average -0.48%
Weighted average by Cap. -0.48%

Financials

2026 *2027 *
Net sales 60Cr 70Cr 8.94Cr 8Cr 7.46Cr 6.77Cr 13Cr 854.79Cr 13Cr 90Cr 35Cr 441.11Cr 34Cr 33Cr 1.42TCr 74Cr 87Cr 11Cr 9.93Cr 9.25Cr 8.39Cr 16Cr 1.06TCr 16Cr 111.2Cr 44Cr 546.98Cr 42Cr 41Cr 1.76TCr
Net income - -
Net Debt -58Cr -68Cr -8.65Cr -7.74Cr -7.22Cr -6.55Cr -12Cr -826.74Cr -12Cr -87Cr -34Cr -426.63Cr -32Cr -32Cr -1.37TCr -65Cr -76Cr -9.69Cr -8.68Cr -8.09Cr -7.34Cr -14Cr -926.75Cr -14Cr -97Cr -38Cr -478.24Cr -36Cr -36Cr -1.54TCr
Projected Income Statement - Annual - Medtide Inc.
Logo Medtide Inc.
Medtide Inc is a China-based company mainly engaged in the contract research, development and manufacturing of peptide. The Company mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The Company's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The Company also provides customers with peptide drug development, production, and CMC filing support services. The Company mainly operates its business in the domestic market and overseas markets.
Employees
596
Date Price Change Volume
13/26/13 HK$20.70 -0.48% 30,000
12/26/12 HK$20.80 +0.19% 72,500
09/26/09 HK$20.76 +0.48% 71,800
08/26/08 HK$20.66 -0.58% 70,800
07/26/07 HK$20.78 +0.87% 71,500
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
17.74CNY
Average target price
19.66CNY
Spread / Average Target
+10.83%

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - Medtide Inc.
  1. Stock Market
  2. Stocks
  3. 3880 Stock